The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth in 2020. Amgen/Novartis’s Aimovig (erenumab) was the first to launch in May 2018, becoming the first migraine-specific preventive therapy, the first MAb for pain, and the first major entrant and biologic to enter this highly underserved but heavily generic market since the approval of Allergan’s Botox for chronic migraine in 2010. This U.S.-based launch-tracking series will assess Aimovig’s uptake and performance during its first year on the market. DRG is also producing a companion series to track the launches of Teva’s Ajovy (fremanezumab) and Eli Lilly’s Emgality (galcanezumab) and provide strategic comparisons between all three products on key metrics.
Questions Answered
How quickly do U.S. neurologists adopt Aimovig, and what percentage of their migraine patients do they consider candidates for the drug?
When and for which migraine patients are neurologists prescribing Aimovig, what are the reasons for prescribing it, and how satisfied are they with the drug?
How do adopters and nonadopters of Aimovig compare across key metrics? What attributes differentiate Aimovig from competing MAbs in the minds of prescribers?
What promotional messages do neurologists recall in support of the Aimovig launch?
Product Description
Emerging Therapies captures U.S. physicians’ awareness, perceptions, and usage of the launched product at one, six, and twelve months postlaunch, as well as the current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, benchmarking against other launched agents, along with statistical comparative analysis with prior waves so that marketers can track and optimize the effectiveness of their launch strategy or fine-tune their product positioning to counter its impact on their brand’s share.
Markets covered: United States.
Primary research: Survey of 75 U.S. neurologists for each wave.
Key metrics included:
Unaided and aided awareness of Aimovig.
Familiarity with and impressions of Aimovig.
Prescriber and nonprescriber profiles.
Willingness to prescribe Aimovig.
Performance of Aimovig on key attributes.
Sales representative visit frequency, reach, and effectiveness.
Migraineu00a0Prophylaxis Emerging Therapies Aimovig US Wave 3u00a0(Julyu00a02019)
Ruchita Kumar, Ph.D.
Ruchita Kumar, M.Pharm., Ph.D.,is a manager on the CNS/Ophthalmology Disorders team at Clarivate. Her specialties are migraine and Alzheimer’s disease. She has worked on a variety of opportunity assessment and market intelligence projects involving the preparation of disease narratives, epi-based forecasts, and building brand performance reports across different therapy areas. She holds a Ph.D. in the design and development of modified-release dosing forms of antidiabetic drugs from the University Institute of Pharmaceutical Sciences at Panjab University in Chandigarh, India.
